Patents Examined by James L Rogers
  • Patent number: 10676503
    Abstract: A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 9, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Kent E. Goklen, Eric J. Suda, Antonio Raul Ubiera
  • Patent number: 10662248
    Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 26, 2020
    Assignees: Subdomain LLC, Arcellx, Inc.
    Inventors: David William Lafleur, David M. Hilbert
  • Patent number: 10654933
    Abstract: The present inventors discovered that additional aggregation of low-pI antibody can be suppressed by removing formed antibody aggregates after a certain period of time following Protein A column purification, acidic treatment, and neutralization. Furthermore, the present inventors found that efficient impurities removal for a low-pI antibody can be accomplished by using an anion exchange resin in the Bind/Elute mode and then a hydrophobic interaction chromatography or multimodal chromatography resin, compared with conventional methods.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: May 19, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yasufumi Ueda, Shohei Kobayashi, Satoko Yanagita, Takuo Kawase, Masahiro Fukunaga
  • Patent number: 10647775
    Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 12, 2020
    Assignees: Subdomain LLC, Arcellx, Inc.
    Inventors: David William Lafleur, David M. Hilbert
  • Patent number: 10647777
    Abstract: Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: May 12, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Kevin P. Brower, Chris Hwang, Rao Koduri, Konstantin B. Konstantinov, Veena Warikoo, Marcella Yu, Jin Yin
  • Patent number: 10633429
    Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 28, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Taizo Uda, Emi Hifumi
  • Patent number: 10626143
    Abstract: The present invention provides a novel method for manufacturing a protein, particularly where said protein is to be coupled with another molecule. The invention further provides a method for industrial scale protein manufacturing to obtain proteins, e.g., for therapeutic purposes.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 21, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Christopher Mark Illidge, Neil Alan Watson
  • Patent number: 10626142
    Abstract: High resolution protein A chromatography employing a chaotropic agent and pH gradient or pH step elution buffer results in improved peak resolution between closely related molecular species. Bispecific antibodies containing a protein A-binding-ablating substitution CH3 domain paired with a protein A-binding CH3 domain are separated with high peak resolution from monospecific antibodies containing a protein A-binding-ablating substituted CH3 domain paired with the protein A-binding-ablating substituted CH3 domain and monospecific antibodies containing a protein A-binding CH3 domain paired with the protein A-binding CH3 domain. Useful chaotropic agents include magnesium chloride and calcium chloride.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: April 21, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Christine Endicott, Benjamin Adams, John Mattila, Hanne Bak
  • Patent number: 10590164
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 17, 2020
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Genentech, INc.
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda
  • Patent number: 10590189
    Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Leonard Bell, Russell P. Rother, Mark J. Evans
  • Patent number: 10556944
    Abstract: An object of the present invention is to provide a Fab region-binding peptide having an excellent ability for binding to a Fab region of IgG, an affinity separation matrix having the peptide as a ligand, and a method for producing a Fab region-containing protein, the method using the affinity separation matrix. Further, another object of the present invention is to provide a DNA encoding for the peptide, a vector containing the DNA, and a transformant which has been transformed by the vector. The Fab region-binding peptide according to the present invention is characterized in having a mutation at a specific site in comparison with wild-type SpG-?1.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: February 11, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata
  • Patent number: 10519195
    Abstract: The first embodiment of the present invention is a method for purifying an antibody or a substance derive from an antibody, wherein a carrier 1 having an affinity ligand with affinity for the antibody or the substance derived from the antibody and a carrier 2 having a cation exchange group are used to prepare an integrated column 1 connecting a column containing the carrier 1 and a column containing the carrier 2 or a column 2 having the mixture of the carrier 1 and carrier 2, the antibody or the substance derived from the antibody is applied to the column 1 or the column 2, and then the adsorbed antibody or substance derived from the antibody is eluted from the column 1 or the column 2. The second embodiment of the present invention is a method for using a carrier having a cation exchange group, wherein a solution containing an antibody or a substance derived from an antibody is applied to a carrier having a cation exchange group having a carboxyl group-containing ligand and pKa of 4.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: December 31, 2019
    Assignee: KANEKA CORPORATION
    Inventor: Kazunobu Minakuchi
  • Patent number: 10519194
    Abstract: The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal, of protein, fragments without adversely affecting the yield of the desired protein product.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Mikhail Kozlov, Matthew T. Stone, Romas Skudas, Kevin Galipeau
  • Patent number: 10508133
    Abstract: This application relates to methods for purification of proteins such as antibodies using a hydrophilic polymer (e.g., PEG), a fatty acid (e.g., caprylic acid), and/or another agent (e.g., calcium chloride).
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: December 17, 2019
    Assignee: NOVASEP PROCESS
    Inventors: Alois Jungbauer, Ralf Sommer
  • Patent number: 10501525
    Abstract: This disclosure relates to methods for isolating antibodies from cell-free culture supernatant.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: December 10, 2019
    Assignee: Novartis AG
    Inventors: Alois Jungbauer, Peter Satzer, Anne-Luise Tscheliessnig
  • Patent number: 10487138
    Abstract: The present invention relates to the purification of immunoglobulins and the problem of providing a method for purifying an immunoglobulin in an efficient and cost-effective manner and with satisfactory purity and yield. In particular, the present invention addresses the aspect of the re-use of the rather cost-intensive chromatography materials, in particular the lifetime of the chromatography materials used in the capture step of the downstream process, and how this can be increased while reducing the technical complexity of the purification process.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: November 26, 2019
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Felföldi, Zsuzsa Benkö, Melinda Gáspár
  • Patent number: 10472389
    Abstract: The present invention provides methods for increasing purity of an Fc-containing protein by removing protein aggregates during the Protein A chromatography step used during the purification of the Fc-containing protein.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 12, 2019
    Assignee: EMD Millipore Corporation
    Inventors: Nanying Bian, Melissa Holstein
  • Patent number: 10472623
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 12, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 10457749
    Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 29, 2019
    Assignee: NovImmune SA
    Inventors: Nicolas Fouque, Jean François Depoisier, Keith Wilson, Judith Vajda, Egbert Müller, Romain Dabre
  • Patent number: 10457720
    Abstract: The present invention refers to a method for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Romas Skudas, Matthias Joehnck, Bianca Edelmann, Simon Braun, Mikhail Kozlov, Matthew T. Stone, Kevin Galipeau